Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863480 · ClinicalTrials.gov registry record · Phase 1
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
A Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06863480 is a Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia that is actively recruiting participants, run by University of Florida. The registered enrollment target is 30 participants, below the 341-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06863480, a Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
Conditions Studied
Interventions
- DRUG tocilizumab-aazg (TYENNE)
Study Locations (1)
Florida
- University of Florida Health (UF Health) - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06863480
The ClinicalTrials.gov registry entry for NCT06863480 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (91% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aneurysmal Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which tocilizumab-aazg (TYENNE) is the first listed.
NCT06863480 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06863480 about?
NCT06863480 is a clinical study titled "Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events". In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
What is the current status of trial NCT06863480?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-02. Estimated completion is 2028-10-30.
What conditions does trial NCT06863480 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia.
What interventions are being tested in trial NCT06863480?
The interventions under investigation include: tocilizumab-aazg (TYENNE) (DRUG).
Who is sponsoring clinical trial NCT06863480?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863480 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysmal Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
RECRUITING · Phase 2
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
-
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
COMPLETED · Phase 3
-
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.